Partial sequence identity in a 25-nucleotide long element is sufficient for transcriptional adaptation in the Caenorhabditis elegans act-5/act-3 model

Genetic robustness can be achieved via several mechanisms including transcriptional adaptation (TA), a sequence similarity-driven process whereby mutant mRNA degradation products modulate, directly or indirectly, the expression of so-called adapting genes. To identify the sequences required for this process, we utilized a transgenic approach in Caenorhabditis elegans, combining an overexpression construct for a mutant gene (act-5) and a fluorescent reporter for the corresponding adapting gene (act-3). Analyzing a series of modifications for each construct, we identified, in the 5’ regulatory region of the act-3 locus, a 25-base pair (bp) element which exhibits 60% identity with a sequence in the act-5 mRNA and which, in the context of a minimal promoter, is sufficient to induce ectopic expression of the fluorescent reporter. The 25 nucleotide (nt) element in the act-5 mRNA lies between the premature termination codon (PTC) and the next exon/exon junction, suggesting the importance of this region of the mutant mRNA for TA. Additionally, we found that single-stranded RNA injections of this 25 nt element from act-5 into the intestine of wild-type larvae led to higher levels of adapting gene (act-3) mRNA. Different models have been proposed to underlie the modulation of gene expression during TA including chromatin remodeling, the inhibition of antisense RNAs, the release of transcriptional pausing, and the suppression of premature transcription termination, and our data clearly show the importance of the regulatory region of the adapting gene in this particular act-5/act-3 TA model. Our findings also suggest that RNA fragments can modulate the expression of loci exhibiting limited sequence similarity, possibly a critical observation when designing RNA based therapies.


Introduction
Under the umbrella of various mechanisms contributing to genetic robustness, or the ability of a living cell or organism to maintain homeostasis in the presence of mutations, transcriptional adaptation (TA) is of particular interest because it regulates gene expression in response to mutant mRNA degradation and not protein feedback loops [1,2]. According to the current model of TA, in the presence of mRNA destabilizing lesions, mRNA degradation products, or their derivatives, translocate from the cytosol to the nucleus where they modulate the mRNA levels of the adapting gene(s). Notably, full locus deletion alleles do not exhibit TA [1,2], indicating that mutant mRNA molecules are required. As such, TA can lead to functional compensation [3][4][5][6][7] or to more severe phenotypes [8] depending on the gene(s) whose expression becomes modulated by the mutant mRNA degradation fragments and/or their derivatives. TA was first described in zebrafish, and offered as an explanation for the differences in phenotypes between knockdown and knockout animals [3]. Subsequently, TA was also reported in mouse cells in culture [1], in Caenorhabditis elegans [4,9], and in the green alga Chlamydomonas reinhardtii [10], suggesting that it is a widespread phenomenon. A major unresolved question about TA concerns the identity of the modulated genes, and initial observations suggest that sequence similarity plays an important role in their selection [1][2][3][4]. Therefore, identifying which sequences in the mutant mRNA are used to select adapting genes and also which sequences in the locus of the adapting genes are important for their modulation will further improve our understanding of the mechanisms underlying TA.
In order to address these questions we used a transgenic approach, which facilitates the identification of sequence elements necessary and sufficient for the TA response, especially when working with essential genes. Working in C. elegans, we have previously reported the ectopic expression of a fluorescent extrachromosomal reporter for act-3 (the adapting gene) in in the intestine of act-5 mutants that display mutant mRNA degradation (i.e., act-5 mutants containing a premature termination codon (PTC) in exon 1) [4]. In a follow-up study, we reported that expression of an act-5(ptc) transgene (eft-3p:act-5(ptc)) leads to increased act-3 mRNA levels as well as the de novo expression of an act-3p:rfp reporter transgene in a tissue where the act-5(ptc) transgene is expressed, namely the uterus [11]. Here, we use two extrachromosomal transgenes, a TA 'driver' (i.e., eft-3p:act-5(ptc)) and a TA 'reporter' (i.e., act-3p: rfp), to identify sequences on both the mutant transcript and the adapting gene locus that are necessary or sufficient for TA. After testing a series of truncations and rearrangements for each transgene, we identified, in the 5' regulatory region of the act-3 locus, a 25-base pair (bp) element that exhibits 60% identity with a sequence in the act-5 mRNA and is sufficient for the TA response. We also tested the element identified in the mutant gene (act-5) by injecting small single-stranded RNAs (ssRNAs) and quantifying the adapting gene (act-3) mRNA levels.

Ectopic uterine RFP expression as a proxy for the transcriptional adaptation response
In order to identify the sequences in the act-3 promoter and in the act-5 mRNA that are necessary and/or sufficient for the TA response of act-3, we utilized two plasmids to generate transgenic animals. The first plasmid [act-3p(long):rfp] uses a 4 kb promoter for the adapting gene (act-3) to drive TurboRFP expression (Fig 1A) [4]. The second plasmid [eft-3p:act-5(ptc)] uses a ubiquitous promoter to overexpress the mutant gene (act-5(ptc)) ( Fig 1B) [11]. By analyzing transgenic animals containing one or both of these plasmids (Fig 1C), or their derivatives, we can identify the sequence requirements by comparing the RFP expression pattern between control and experimental animals. For this study, we define 'control animals' as animals injected with only the [act-3p:rfp] reporter (Fig 1D), and 'experimental animals' as animals injected with both the [act-3p:rfp] reporter and [eft-3p:act-5(ptc)] overexpression constructs ( Fig 1E). For all transgene modification experiments, we compared the reporter expression pattern between control and experimental animals at the adult stage when the differences between uterus expression patterns are most evident (S1 Fig).
We first analyzed the [act-3p(long):rfp] reporter and observed its expression in the pharynx, body wall, and spermatheca of transgenic animals (Figs 1D, S1A, and S1C), a pattern consistent with tissues known to express act-3 [11][12][13]. We then asked whether there was a change in expression when the [act-3p(long):rfp] reporter was co-injected with the [eft-3p:act-5(ptc)] overexpression construct, and observed an additional and strong RFP signal in the uterus of adult animals (Figs 1E, S1B, and S1D), as we previously reported [11]. This ectopic uterine expression phenotype is similar to the ectopic intestinal expression phenotype observed when the [act-3p(long):rfp] reporter was exposed to the dt2019(act-5(ptc)) mutation [4], in that we observe an expansion of the reporter expression into act-5(ptc) expressing tissues, indicating that we can use this system to visualize TA.
To further test whether the observed change in reporter expression was indeed due to TA, we co-injected the act-3p:rfp reporter and act-5(ptc) overexpression constructs into both the ergo-1(gg100) and rrf-3(mg373) mutant backgrounds [14]. We had previously reported that upregulation of the adapting gene (act-3) was blocked in both act-5(ptc);ergo-1 and act-5(ptc); rrf-3 double mutants [4]. Consistent with these data, we found that there was no uterine expression of the [act-3p(long):rfp] reporter when co-injected with the act-5(ptc) overexpression construct in either of these mutant backgrounds (S2 Fig), further supporting the conjecture that in these experimental animals, TA drives the expression of RFP in the uterus.

base pairs in the act-3 promoter are sufficient for the transcriptional adaptation response
In order to determine which sequences in the act-3 promoter are sufficient for TA, we first needed to identify a minimal promoter-driven reporter that exhibits no change in expression when co-injected with the act-5(ptc) overexpression construct. As many promoters in C. elegans are in the range of 1 to 2 kb [15], we removed 2.6 kb from the 5' end of the [act-3p(long): rfp] reporter leaving 1.4 kb directly upstream of the act-3 translational start codon (Fig 2A). With this [act-3p(short):rfp] reporter, we observed RFP expression only in the pharynx in both the control and experimental animals (i.e., no difference in RFP expression) (Fig 2A), reporter construct for the adapting gene (act-3), i.e., the TA 'reporter'. A 4 kb sequence directly 5' of the act-3 translational start codon drives TurboRFP expression [4]. (B) Diagram of the overexpression construct for the mutant gene (act-5) [11], i.e., the TA 'driver'; the ubiquitous eft-3 promoter drives expression of the complete act-5(ptc) sequence including exons (E), and introns (bent lines); PTC marked with a red line. (C) Methodology for transgenic line generation: P0 WT animals were injected with a plasmid mix, fluorescent F1s were selected for line isolation, and expression patterns were analyzed starting in the third generation. (D) Representative image and cartoon of an animal containing only the act-3p:rfp reporter construct displaying reporter expression in the pharynx, body wall, and spermatheca [11]. (E) Representative image and cartoon of an animal containing both the act-3p:rfp reporter and act-5(ptc) overexpression constructs displaying reporter expression in the pharynx, body wall, spermatheca, and uterus. n = number of animals exhibiting the representative phenotype over the number of fluorescent animals screened. Cartoons were generated using Biorender.com (full license). Scale bars = 100 μm. https://doi.org/10.1371/journal.pgen.1010806.g001

PLOS GENETICS
Sequence requirements for transcriptional adaptation in C. elegans suggesting that a sequence from the 2.6 kb region that was removed from the [act-3p(long):rfp] reporter is involved in TA.
Next, we added sequences from this 2.6 kb region to the 5' end of the [act-3p(short):rfp] reporter to test for sufficiency, as well as tested internal deletions in the long promoter to test for necessity. For example, when we deleted 1.1 kb from the middle of the 2.6 kb region [act-3p(long-1.1kb):rfp] (see methods), we observed ectopic reporter expression in the uterus when it was co-injected with the act-5(ptc) overexpression construct (S3 Fig), suggesting that this element is not necessary for TA. However, when a 187 bp sequence from the distal end of the long promoter was added to the 5' end of the [act-3p(short):rfp] reporter ([act-3p(187+short): rfp]), we observed ectopic reporter expression in the uterus when it was co-injected with the act-5(ptc) overexpression construct (Fig 2B), suggesting that this 187 bp element is sufficient for TA in the context of the short/minimal promoter.
We note that the long promoter overlaps with the neighboring gene act-2 (S4A Fig) [16]. Therefore, to determine which sub-sequence was sufficient for TA, the 187 bp was split into two parts (see methods). The first part consists of 162 bp of mostly exonic sequence; the second part consists of 25 bp of intronic sequence (S4B Fig). We found that when the 162 bp element was added onto the 5' end of the short promoter reporter [act-3p(162+short):rfp] and this construct was coinjected with the act-5(ptc) overexpression construct, RFP expression from the reporter was observed only in the pharynx (S4C Fig), suggesting that this 162 bp element is not sufficient for TA.
However, when the 25 bp element was added to the 5' end of the short promoter reporter [act-3p(25+short):rfp], we first observed ectopic reporter expression in the intestine of the control animals in addition to expression in the pharynx (Fig 2C left panel), suggesting that in this particular location and in the absence of act-5(ptc) expression, this 25 bp element can act as an enhancer sequence. Additionally, when this [act-3p(25+short):rfp] reporter was coinjected with the act-5(ptc) overexpression construct, we observed ectopic reporter expression in the uterus ( Fig 2C right panel), suggesting that this 25 bp element is sufficient for TA in the context of the short/minimal promoter. In these experimental animals, intestinal expression was lost ( Fig 2C right panel), suggesting that the mechanism of action of the enhancer effect (i.e., intestinal expression ( Fig 2C left panel)) and TA are mutually exclusive, as has been reported for other transcription regulatory processes [17]. Notably, adding 10, 13, or 16 bases of this 25 bp element to the 5' end of the short/minimal promoter was not sufficient to induce TA, indicating that the minimal length of the sufficient sequence is between 17 and 25 bp (S1 Table).

Deleting the 25 bp sequence in the act-3 reporter leads to its ectopic expression in the uterus
To investigate whether this 25 bp element is necessary for TA, we deleted it from the [act-3p (long):rfp] reporter ([act-3p(25 removed):rfp]) and observed ectopic uterine expression in both the control and experimental (i.e., when coinjected with the act-5(ptc) overexpression construct) animals ( Fig 3A). These data suggest that this 25 bp sequence is an important regulatory element of the act-3 promoter, where it may be bound by a repressor. We made similar observations when we unmatched the 25 bp sequence [act-3p (25 unmatched):rfp] (S1 Table), finding ectopic reporter expression in the uterus in both the control and experimental animals ( Fig  3B), suggesting that the sequence of this element is critical for its function. expression in the pharynx and uterus. Worms outlined with a white dotted line; n = number of animals exhibiting the representative phenotype over the number of fluorescent animals screened. Cartoons were generated using Biorender. com (full license). Scale bars = 100 μm. https://doi.org/10.1371/journal.pgen.1010806.g002

PLOS GENETICS
Sequence requirements for transcriptional adaptation in C. elegans To investigate whether this 25 bp element plays a similar regulatory role in the endogenous locus, we deleted most of this element (leaving only one base behind to maintain the splice donor sequence in the neighboring gene, see methods), and observed that act-3 was significantly upregulated in such mutants (S5A Fig). This result strengthens the suggestion that this 25 bp element is likely bound by a transcriptional repressor in its endogenous context, and that its removal, or alteration, leads to increased mRNA levels, independently of TA.

Removing the 25-base pair sequence from the act-5(ptc) transgene diminishes the transcriptional adaptation response
To identify the act-5 sequence that corresponds to the 25 bp element in the act-3 promoter, we performed a sequence identity search (see methods). We identified four locations within the act-5 sequence that are most similar to the 25 bp act-3 sequence (60% identity) ( Fig 4A); one is located in the first exon, another in the first intron, and the other two in the 3' UTR. We excluded the intron element since it is not present in the mature RNA, and decided to focus on the 25 bp element located in the first exon of act-5 as it contains the highest G/C content and thus would exhibit the greatest binding affinity between the two loci.
To determine whether this 25 bp element in act-5 is necessary for TA in these transgenic conditions, we first shuffled its codons [18] to conserve the amino acid sequence of ACT-5 but reduce the identity as much as possible between the act-5 and act-3 DNA sequences, thereby reducing the identity from 60% to a final identity of 40% (Fig 4A). We found that in these experimental animals, co-injection of the [eft-3p:act-5(ptc:25 shuffled)] overexpression construct could induce uterine expression of the [act-3p(long):rfp] reporter (Fig 4B), suggesting that this particular 25 bp element from act-5 is not necessary for TA, or that 40% identity between the two sequences is sufficient. We then removed this 25 bp element from the act-5 (ptc) plasmid and observed a significant reduction (P = 0.0124) in the percentage of experimental animals displaying ectopic uterine expression of the RFP reporter ( Fig 4C): 73% of the  (Fig 1D), suggesting that the removal of this element from act-5 affects the efficacy of the TA effect. These results suggest that other elements in the mutant mRNA may play a role in the TA response, or that in this experimental scenario, TA is induced indirectly by the [eft-3p:act-5(ptc:25 removed)] transgene via the triggering of an endogenous RNAi pathway [19] that leads to the degradation of the endogenous act-5 mRNA.

nucleotide long single-stranded RNA injections lead to higher levels of act-3 mRNA
To determine whether 25 nt of RNA from act-5 are sufficient to alter the mRNA levels of the endogenous adapting gene (act-3), we injected both sense and antisense single-stranded RNA (ssRNA) [20] into the gut of wild-type L3 larvae. After a 21-hour recovery period, worms were collected for single worm RT-qPCR [21] to assess the effects of act-5 ssRNA injections on act-3 mRNA levels; and we also assessed act-5 mRNA levels (since the act-5 ssRNAs match the act-5 sequence exactly and they could have some RNA interfering activity) (Fig 5A). In order to control for the effects of the physical trauma of injection, and for any physiological alterations due to the presence of excess ssRNA, we injected water as well as a non-targeting 25 nt eGFP sequence. We observed no significant difference between water and eGFP ssRNA injections in WT animals in terms of act-3 and act-5 mRNA levels. (Fig 5B and 5C).
We found that injecting sense or antisense act-5 ssRNA caused significant upregulation of act-3 (Fig 5B), but had no effect on act-5 mRNA levels (Fig 5C), when compared with controls,

PLOS GENETICS
Sequence requirements for transcriptional adaptation in C. elegans suggesting that the TA effect on the adapting gene (act-3) can be triggered by ssRNA matching the appropriate sequence from the mutant gene (act-5).
To assess whether the act-5 ssRNAs are inducing act-3 upregulation via TA, we performed injections into ergo-1 mutants, which we previously reported fail to exhibit TA [4]. We found that, when compared with controls, injecting sense act-5 ssRNA into ergo-1 mutants caused no significant change in act-3 mRNA levels, while injecting antisense act-5 ssRNA caused a significant decrease in act-3 mRNA levels (Fig 5D). In addition, there were no significant changes in act-5 mRNA levels following act-5 ssRNA injections into this mutant background (Fig 5E), suggesting that ergo-1 is required for the increase in act-3 mRNA levels after act-5 ssRNA injections, and that the sense and antisense act-5 ssRNA molecules may be used by different mechanisms to increase act-3 mRNA levels in WT.
To further test whether the ssRNAs were inducing act-3 upregulation via TA, we also performed injections into rrf-3 mutants, which we previously reported also fail to exhibit TA [4]. We found that injecting eGFP ssRNA caused a non-significant decrease in act-3 mRNA levels (Fig 5F), and a significant decrease in act-5 mRNA levels (Fig 5G), suggesting that any ssRNA injections into this hypersensitive RNAi mutant [22] can lead to a global RNAi effect. We also found that injecting sense or antisense act-5 ssRNA into rrf-3 mutants caused a significant downregulation of both act-3 and act-5 mRNA levels (Fig 5F and 5G), when compared with water injected controls, possibly suggesting that rrf-3 is required for the upregulation of act-3 after act-5 ssRNA injections.
To assess whether act-5 ssRNA injections could induce upregulation of act-3 when the 25 bp element was removed from its regulatory region, we performed injections into a deletion mutant. We observed no significant changes in act-3 mRNA levels following act-5 ssRNA injections into act-2(knu112) mutant animals when compared with controls (S5C Fig), suggesting that the effect induced by act-5 ssRNA injections does not occur, or is masked (i.e., there is no additive effect/no significant change from the increased levels already present in these mutants), when the 25 bp element is removed from the act-3 regulatory region. However, we observed significant upregulation of act-5 in these mutant animals following antisense act-5 ssRNA injection (S5D Fig), further suggesting that sense and antisense act-5 ssRNA injections are modulating different regulatory mechanisms.

Discussion
Transcriptional adaptation (TA) is a widespread cellular response to mRNA destabilizing lesions, including mutations, that is driven by mRNA degradation fragments, or their derivatives [1][2][3][4][5][6][7]11]. TA could lead to changes in gene expression via different mechanisms including chromatin remodeling [1,2,11], the inhibition of antisense RNAs [1], the release of transcriptional pausing [23], and the suppression of premature transcription termination [1][2][3][4]9]. Here, starting with a 4 kb piece of the act-3 locus that includes the first exon and first intron as well as 2.8 kb of upstream sequence, we identified a 25 bp element 2.6 kb upstream of the transcriptional start site of the adapting gene (act-3) that is sufficient for TA in a transgenic setting. The corresponding 25 nt element in the mutant mRNA (act-5) lies between the PTC and the next exon/exon junction, suggesting the importance of this region of the mutant mRNA.

PLOS GENETICS
Sequence requirements for transcriptional adaptation in C. elegans Generally, PTC containing transcripts are thought to initiate non-sense mediated mRNA decay (NMD) through stalling of the ribosome at the location of the PTC, and to lead to complete degradation of the aberrant mRNA molecule by the exosome and the exoribonuclease XRN1 [24]. Previous studies have shown that mRNA degradation via NMD can begin with endonucleolytic cleavage at the location of the PTC or slightly 3' (i.e., downstream) of the PTC [25,26], and another study indicates that different locations of the PTC lead to different TA effects [9]. Therefore, although degradation is thought to produce primarily single bases [27][28][29], our observations that an important element for TA lies between the PTC and the next exon/exon junction and that ssRNAs matching a mutant locus can lead to higher levels of adapting gene (act-3) mRNA suggest that mRNA degradation may also produce small fragments unique to a given mutation. These fragments could arise due to their being protected by NMD machinery proteins, secondary structures in the mRNA itself, or by the stalling of XRN1 during degradation [30].
The approach we used to identify elements involved in TA in the act-5/act-3 model was focused specifically on the 5' regulatory region of act-3 since we had previously found that it was sufficient for the TA response using transgenic reporters [4]. It is important to note that other elements in the act-3 locus may also play a role. For example, a 25 bp sequence with 60% identity to the 25 bp act-5 element is also present in the third intron of act-3, and we have not tested its function. However, act-2 is not upregulated in act-5(ptc) mutants [4], suggesting that the 25 bp element in intron 2 of act-2 we found to be sufficient for upregulation of the act-3 reporter in the presence of the act-5(ptc) transgene does not play a similar role in the regulation of act-2 expression.
We also note that removal of the 25 bp element from the act-3 reporter induces its ectopic expression (suggesting that this element is bound by a transcriptional repressor), that TA results in the upregulation of the adapting gene (act-3) [4], and that a small RNA matching part of the mutant gene's mRNA can lead to higher levels of adapting gene (act-3) mRNA. Altogether, these data lead us to suggest that in this TA model, small RNA(s) derived from the mutant gene's (act-5) mRNA and bound by an RNA binding protein, translocate to the nucleus [31] and interact with the repressor element in the regulatory region of the adapting gene (act-3) enabling its activation. While the end result appears similar to what is observed during RNA activation [32,33], the underlying mechanisms might be quite different. Additionally, the limited sequence similarity between the 25 bp elements (60% identity) has implications for gene expression regulation on a broader scale, and we suggest that although TA was first observed as a functionally compensating mechanism [3,[5][6][7], RNA-driven gene regulation may have broader effects due to the nonspecific ways small RNAs can recognize their targets [34,35].

C. elegans culture conditions and strains
All C. elegans strains were maintained on 6 cm plates with nematode growth medium agar and fed with a lawn of E. coli OP50 grown in 500 μl Luria broth [36]. All C. elegans strains used in this study are listed in Table 1. Cultures were maintained at 18-20˚C. In addition, to minimize the potential for laboratory evolution of the traits, new cultures of the strains were revived annually from frozen stocks. All plates with fungal or bacterial contamination were excluded from the experiments.

C. elegans transgenic and mutant line generation
Injections for generation of RFP reporter lines were performed as previously described [37,38], with the following modifications. Plasmids were purified twice using the FastGene COP2474-act-2(knu112) and COP2475-act-2(knu113) mutant strains were generated by InVivo Biosystems using a Cas12a mediated single strand donor knock-in strategy. A unique CRISPR target in the act-2 intron was selected to prevent off-target cutting at the act-3 and act-1 loci. The donor oligo utilized homology on both sides of the 24 bp sequence (genomic location C. elegans PRJNA13758:WBcel235:V:11077086:11077109) [16] so that the resulting mutation would retain the splice donor and remove the majority of the 25 bp element (genomic location C. elegans PRJNA13758:WBcel235:V:11077086:11077110) [16]. These two mutants appear identical based on sequencing their act-2 locus. Genotyping primers are listed in S2 Table. C. elegans construct generation The previously described [eft-3p::act-5(ptc)] transgene [11] was cloned into a smaller vector backbone (pCFJ1662, a gift from Erik Jorgensen (Addgene plasmid # 51482; http://n2t.net/ addgene:51482; RRID:Addgene_51482)) between the minimos transposon arms using Gibson ] overexpression constructs were generated by site-directed mutagenesis. The 1.1 kb deletion was designed to delete three lncRNAs present in the act-3 promoter region. Initial experiments with a truncation series in the dt2019 (endogenous act-5(ptc)) mutant background suggested that removal of 187 bp from the 5' end of the [act-3p(long):rfp] reporter affected the TA response (S3 Table).
To investigate whether the 187 bp sequence was necessary for TA, we deleted it from the [act-3p(long):rfp] reporter ([act-3p(long-187):rfp]) and observed ectopic reporter expression in the uterus of both the control and experimental animals (S1 Table), suggesting that this 187 bp sequence contains an important regulatory element of the act-3 promoter. The 187 bp element was split into 162 bp of more conserved sequence (161 bp of act-2 exon 2 sequence plus the first base of the splice donor), and 25 bp of less conserved sequence starting at the second base of the slice donor and including the rest of the 187 bp sequence. Further dissection of the 25 bp element (i.e., 10, 13, and 16 bp) added to the 5' end of the [act-3p(short):rfp] reporter) was designed in 3 bp increments starting from the middle of the sequence.
Sequences of the constructs are listed in S1 Table. Primers used for cloning are listed in S2 Table. The key plasmids used in this study have been deposited at Addgene.

C. elegans screening
From the third generation onwards, plates of transgenic animals were scored on days five or six of their life cycle when gravid adults were present but before the plates began to starve. Only fluorescent adult animals were scored, and only if the entire pharynx appeared to be expressing RFP under a dissection microscope. Animals were categorized as pharynx only, pharynx plus uterus, or pharynx plus intestine. The ratio of fluorescent animals was taken as the number of animals displaying only pharynx RFP expression over the total number of screened animals at each generation. The significance of this ratio was calculated using Welsh's T-test comparing each experimental condition to the appropriate control condition. Raw counts, fluorescent ratios, and P values are listed in S1 Table. C. elegans sequence comparison The program A Plasmid Editor (ApE) [40] (version 2.0.70.0) was used to perform sequence identity searches for short sequence lengths. Using the identified 25 bp element from the act-3 promoter as the query sequence, the "Find. . ." function within ApE was used to identify matching locations within the act-5 locus (genomic location C. elegans PRJNA13758: WBcel235:III:13604322:13606215) [16]. Searches were performed sequentially allowing for one additional mismatch each round until a sequence within act-5 was identified as matching the query sequence. Four sequences were identified with 10 mismatches (60% identity): one is located in the first exon (40% G/C content), another in the first intron (24% G/C content), and the other two in the 3' UTR (8% and 16% G/C content). Comparing the 25 bp act-3 promoter sequence to the act-5 mRNA sequence identifies the same exonic sequence and the same two 3' UTR sequences.

ssRNA microinjections
ssRNA microinjections [20] were performed with the following modifications. ssRNAs were synthesized by Merck or Integrated DNA Technologies with 5' phosphorylation and 3' 2-O methylation for stability [41]. ssRNAs were resuspended to a final injection concentration of 100 μM in DNase/RNase free water, and around 80 pg was injected into the gut of L3 larvae. The injected larvae were allowed to recover for 21 hours and then collected for RNA isolation at the L4 stage (i.e., before eggs are present). Obviously sick or dying worms were excluded from these experiments. ssRNA sequences are listed in S2 Table. RT-qPCR analysis RT-qPCR was performed using a CFX Connect Real-Time System (Biorad) or QuantStudio 7 Pro Real-Time PCR System (Applied Biosystems). Single C. elegans worms were collected for RNA isolation as previously described [21] with the following changes. Worms were collected into 2 μl of lysis buffer, cDNA synthesis was performed using the Maxima First Strand cDNA synthesis kit (Thermo Fisher) as half reactions using the entire 2 μl of RNA as template, cDNA was diluted to 14 μl with water, and 1 μl of cDNA was used for each qPCR reaction. For the analysis of act-2(knu112) and act-2(knu113) mutants (S5A and S5B Fig), pools of synchronized L1/L2 animals were collected and 1-2 μg of RNA was used for the reverse transcription reaction as previously described [1,4,11]. All reactions were performed in at least technical duplicates and the results represent biological replicates of n � 4. cdc-42 was used as the sole reference gene as it was found to be the only reliable one out of four tested (cdc-42, Y45F10D.4, pmp-3, and tba-1). Primer sequences used for the RT-qPCR experiments are listed in S2 Table. Fold changes were calculated using the 2−ΔΔCt method in groups of experiments performed at the same time to control for batch effects. All Ct values and analysis groups are listed in S4 Table. Microscopy Fluorescence images of single C. elegans were acquired using a Zeiss LSM 700 confocal microscope (Plan-Apochromat 10X/0.45 objective lens). Group images of C. elegans were acquired using a Nikon SMZ25 dissection microscope (SHR Plan Apo 1x WD:60 objective lens) equipped with a Nikon Digital Sight DS-Ri1 camera. Worms were immobilized by mounting them in polystyrene microbeads [42]. Images were processed with ZEN software (black edition). All figures were prepared using Microsoft PowerPoint.

Cartoons
Cartoons were generated using Biorender.com (full license).

Statistics and reproducibility
Statistical analysis was performed using GraphPad Prism 8. Data are mean ± s.d., and a twotailed Welch's t-test was used to calculate P values. No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. All experiments were performed at least twice unless otherwise noted. P values for all pairwise comparisons for ssRNA injections are listed in S5 Table. P < 0.05 was accepted as statistically significant. and act-2(knu113) mutant animals. n � 5 biologically independent samples. Data compared with WT controls. (C) Relative mRNA levels of act-3 in act-2(knu112) mutant animals injected with water, eGFP ssRNA, sense act-5 ssRNA, and antisense act-5 ssRNA. (D) Relative mRNA levels of act-5 in act-2(knu112) mutant animals injected with water, eGFP ssRNA, sense act-5 ssRNA, and antisense act-5 ssRNA. n � 6 biologically independent samples. Data compared with water injected controls. Data are mean ± s.d., and a two-tailed Welch's t-test was used to calculate P values. Ct values are listed in S4 Table. (TIF) S1 Table. Raw count data, and sequence information.